Clinicaltrials.gov identifier:
NCT02620852 (https://clinicaltrials.gov/show/NCT02620852)
Prevention
Study Contact Information:
The study is being conducted by researchers at the University of California and at Sanford Health in the Midwest. Contact Information: by phone at 855-729-2844 or by email.
The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. For more information, visit the WISDOM Study website.
This Wisdom Study is a preference-tolerant randomized controlled trial. This means that there are two study participation options: randomization or self-selection. If a woman elects to be randomized, she will be randomly assigned to either a personalized screening schedule or an annual screening schedule. If a woman prefers to choose her own screening schedule, she may choose to participate in either the personalized or annual screening group.
Participants in both groups will then be asked to complete annual follow-up surveys in the years to come about changes in their breast health.
Participation is done completely online by signing up at wisdomstudy.org. There is no need to come to a participating center as the study can be completed at home. By joining the study, every woman will gain a better understanding of her personalized breast cancer risk, but also help us chart the way forward for breast cancer screening and prevention.
Stepwise process:
*Some insurance companies have partnered with the Wisdom Study and are covering the genetics test as part of their covered services. Please note that no individual woman will be billed for the genetics test. It will be covered by participating insurers or by the study.
Laura Esserman, MD MBA: University of California San Francisco
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.